

James B Yu, Mhs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3889179/publications.pdf>

Version: 2024-02-01

364
papers

13,058
citations

23567

58
h-index

31849

101
g-index

369
all docs

369
docs citations

369
times ranked

15747
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 976-983.	10.7	846
2	Management of Brain Metastases in Tyrosine Kinase Inhibitor- and Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 1070-1077.	1.6	372
3	Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. <i>Radiotherapy and Oncology</i> , 2020, 148, 157-166.	0.6	352
4	Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 655-663.	10.7	335
5	Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. <i>Journal of Neurosurgery</i> , 2012, 117, 227-233.	1.6	296
6	A retrospective review of 1349 cases of sebaceous carcinoma. <i>Cancer</i> , 2009, 115, 158-165.	4.1	288
7	Extended Survival and Prognostic Factors for Patients With <i>ALK</i> -Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. <i>Journal of Clinical Oncology</i> , 2016, 34, 123-129.	1.6	284
8	Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 52-60.	1.6	218
9	Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. <i>Blood</i> , 2011, 117, 412-418.	1.4	217
10	Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. <i>JAMA Oncology</i> , 2018, 4, 1375.	7.1	215
11	Use of Alternative Medicine for Cancer and Its Impact on Survival. <i>Journal of the National Cancer Institute</i> , 2018, 110, 121-124.	6.3	198
12	Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?. <i>Journal of Neurosurgery</i> , 2016, 125, 17-23.	1.6	192
13	Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance. <i>Journal of Clinical Oncology</i> , 2015, 33, 3177-3185.	1.6	187
14	Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. <i>Cancer</i> , 2016, 122, 3051-3058.	4.1	182
15	Artificial intelligence in radiation oncology: A specialty-wide disruptive transformation?. <i>Radiotherapy and Oncology</i> , 2018, 129, 421-426.	0.6	175
16	Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 215-219.	1.1	167
17	Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 812-816.	0.8	163
18	Immortal Time Bias: A Frequently Unrecognized Threat to Validity in the Evaluation of Postoperative Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1365-1373.	0.8	156

#	ARTICLE	IF	CITATIONS
19	Population Based Cancer Registry Analysis of Primary Tracheal Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 32-37.	1.3	154
20	Determinants and Patterns of Survival in Adenoid Cystic Carcinoma of the Head and Neck, Including an Analysis of Adjuvant Radiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 76-81.	1.3	151
21	Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity. Journal of the National Cancer Institute, 2013, 105, 25-32.	6.3	151
22	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances in Radiation Oncology, 2020, 5, 659-665.	1.2	149
23	Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer, 2012, 118, 4212-4219.	4.1	144
24	Pretreatment Identification of Head and Neck Cancer Nodal Metastasis and Extranodal Extension Using Deep Learning Neural Networks. Scientific Reports, 2018, 8, 14036.	3.3	139
25	Superior Vena Cava Syndrome—A Proposed Classification System and Algorithm for Management. Journal of Thoracic Oncology, 2008, 3, 811-814.	1.1	133
26	Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Comparison of Toxicity. Journal of Clinical Oncology, 2014, 32, 1195-1201.	1.6	133
27	NCI SEER public-use data: applications and limitations in oncology research. Oncology, 2009, 23, 288-95.	0.5	129
28	Phosphorylated FADD induces NF- κ B, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 12507-12512.	7.1	122
29	Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. JAMA Oncology, 2020, 6, 1028.	7.1	122
30	Age, Race, Sex, Stage, and Incidence of Cutaneous Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 291-296.	0.4	119
31	Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population. Journal of Clinical Oncology, 2012, 30, 1601-1607.	1.6	112
32	Overview of the Surveillance, Epidemiology, and End Results Database: Evolution, Data Variables, and Quality Assurance. Current Problems in Cancer, 2012, 36, 183-190.	2.0	112
33	Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 44-54.e9.	0.8	105
34	Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor—Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2016, 95, 673-679.	0.8	102
35	Limitations and Biases of the Surveillance, Epidemiology, and End Results Database. Current Problems in Cancer, 2012, 36, 216-224.	2.0	98
36	Historical Trends in the Use of Radiation Therapy for Pediatric Cancers: 1973-2008. International Journal of Radiation Oncology Biology Physics, 2013, 85, e151-e155.	0.8	97

#	ARTICLE	IF	CITATIONS
37	Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2727-2734.	1.6	95
38	Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1304-1311.	1.6	95
39	Whole Pelvic Radiotherapy Versus Prostate Only Radiotherapy in the Management of Locally Advanced or Aggressive Prostate Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1344-1349.	0.8	83
40	Gamma Knife radiosurgery for sellar and parasellar meningiomas: a multicenter study. <i>Journal of Neurosurgery</i> , 2014, 120, 1268-1277.	1.6	83
41	The Association Between Diffusion of the Surgical Robot and Radical Prostatectomy Rates. <i>Medical Care</i> , 2011, 49, 333-339.	2.4	82
42	A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5523-5532.	7.0	82
43	Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 334-343.	0.8	81
44	Gamma Knife radiosurgery for posterior fossa meningiomas: a multicenter study. <i>Journal of Neurosurgery</i> , 2015, 122, 1479-1489.	1.6	79
45	Radiation Therapy Definitions and Reporting Guidelines for Thymic Malignancies. <i>Journal of Thoracic Oncology</i> , 2011, 6, S1743-S1748.	1.1	78
46	Association Between Geographic Access to Cancer Care and Receipt of Radiation Therapy for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 719-728.	0.8	78
47	Surveillance, Epidemiology, and End Results (SEER) Database Analysis of Microcystic Adnexal Carcinoma (Sclerosing Sweat Duct Carcinoma) of the Skin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 125-127.	1.3	77
48	Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer. <i>Cancer</i> , 2015, 121, 2341-2349.	4.1	74
49	Treatment-Related Complications of Systemic Therapy and Radiotherapy. <i>JAMA Oncology</i> , 2019, 5, 1028.	7.1	73
50	Adoption of Hypofractionated Whole-Breast Irradiation for Early-Stage Breast Cancer: National Cancer Data Base Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 993-1000.	0.8	72
51	Estimating the magnitude of colorectal cancers prevented during the era of screening: 1976 to 2009. <i>Cancer</i> , 2014, 120, 2893-2901.	4.1	71
52	Considerations for Observational Research Using Large Data Sets in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 11-24.	0.8	70
53	mTOR Controls Ovarian Follicle Growth by Regulating Granulosa Cell Proliferation. <i>PLoS ONE</i> , 2011, 6, e21415.	2.5	69
54	Sequence Assembly of <i>Yarrowia lipolytica</i> Strain W29/CLIB89 Shows Transposable Element Diversity. <i>PLoS ONE</i> , 2016, 11, e0162363.	2.5	68

#	ARTICLE	IF	CITATIONS
55	Patterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population From 2008â€“2009. <i>Journal of Clinical Oncology</i> , 2012, 30, 4302-4307.	1.6	67
56	Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Nonâ€“Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 937-943.	1.1	66
57	Assessment of National Practice for Palliative Radiation Therapy for Bone Metastases Suggests Marked Underutilization of Single-Fraction Regimens in the United States. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 548-555.	0.8	66
58	Prevalence of Missing Data in the National Cancer Database and Association With Overall Survival. <i>JAMA Network Open</i> , 2021, 4, e211793.	5.9	66
59	Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in nonâ€“small cell lung cancer with brain metastases. <i>Journal of Neurosurgery</i> , 2020, 132, 512-517.	1.6	62
60	Changing practice patterns of Gamma Knife versus linear accelerator-based stereotactic radiosurgery for brain metastases in the US. <i>Journal of Neurosurgery</i> , 2016, 124, 1018-1024.	1.6	61
61	Status Quoâ€“Standard-of-Care Medical and Radiation Therapy for Glioblastoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 12-19.	2.0	60
62	Impact of Widespread Cervical Cancer Screening. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 289-294.	1.3	60
63	Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. <i>Radiotherapy and Oncology</i> , 2009, 93, 185-191.	0.6	58
64	The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1069-1077.	0.8	58
65	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. <i>Radiotherapy and Oncology</i> , 2017, 125, 80-88.	0.6	58
66	Radiosurgery for Brain Metastases: Changing Practice Patterns and Disparities in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1494-1502.	4.9	57
67	A Prognostic Index for Predicting Lymph Node Metastasis in Minor Salivary Gland Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 169-175.	0.8	55
68	Treatment of Primary Cutaneous CD30+ Anaplastic Large-Cell Lymphoma With Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1542-1545.	0.8	52
69	Long-term response to fractionated radiotherapy of presumed optic nerve sheath meningioma. <i>British Journal of Ophthalmology</i> , 2010, 94, 559-563.	3.9	52
70	Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4240-4246.	1.6	52
71	Gamma knife stereotactic radiosurgical thalamotomy for intractable tremor: A systematic review of the literature. <i>Radiotherapy and Oncology</i> , 2015, 114, 296-301.	0.6	51
72	The cost implications of prostate cancer screening in the Medicare population. <i>Cancer</i> , 2014, 120, 96-102.	4.1	50

#	ARTICLE	IF	CITATIONS
73	Stereotactic radiosurgery of petroclival meningiomas: a multicenter study. <i>Journal of Neuro-Oncology</i> , 2014, 119, 169-176.	2.9	50
74	Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers. <i>JAMA Oncology</i> , 2015, 1, 185.	7.1	50
75	Geographic Analysis of the Radiation Oncology Workforce. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1723-1729.	0.8	49
76	Validation of the Partin Nomogram for Prostate Cancer in a National Sample. <i>Journal of Urology</i> , 2010, 183, 105-111.	0.4	47
77	Stage I Lung SBRT Clinical Practice Patterns. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 358-361.	1.3	47
78	Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. <i>Neuro-Oncology</i> , 2018, 20, 1652-1660.	1.2	47
79	National Patterns in Prescription Opioid Use and Misuse Among Cancer Survivors in the United States. <i>JAMA Network Open</i> , 2020, 3, e2013605.	5.9	47
80	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. <i>BJU International</i> , 2016, 118, 95-101.	2.5	45
81	Poorer Prognosis of African-American Patients With Mycosis Fungoides: An Analysis of the SEER Dataset, 1988 to 2008. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 419-423.	0.4	43
82	Shared Decision Making and Use of Decision Aids for Localized Prostate Cancer. <i>JAMA Internal Medicine</i> , 2015, 175, 792.	5.1	43
83	The Population Level Prevalence and Correlates of Appropriate and Inappropriate Imaging to Stage Incident Prostate Cancer in the Medicare Population. <i>Journal of Urology</i> , 2012, 187, 97-102.	0.4	42
84	Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer. <i>Medical Care</i> , 2014, 52, 579-585.	2.4	42
85	Analysis of Primary CD30+ Cutaneous Lymphoproliferative Disease and Survival From the Surveillance, Epidemiology, and End Results Database. <i>Journal of Clinical Oncology</i> , 2008, 26, 1483-1488.	1.6	41
86	A New Formula for Prostate Cancer Lymph Node Risk. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 69-75.	0.8	40
87	The Adoption of New Adjuvant Radiation Therapy Modalities Among Medicare Beneficiaries With Breast Cancer: Clinical Correlates and Cost Implications. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1186-1192.	0.8	40
88	Variation in Pelvic Lymph Node Dissection among Patients Undergoing Radical Prostatectomy by Hospital Characteristics and Surgical Approach: Results from the National Cancer Database. <i>Journal of Urology</i> , 2015, 193, 820-825.	0.4	40
89	The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	40
90	Comparing available criteria for measuring brain metastasis response to immunotherapy. <i>Journal of Neuro-Oncology</i> , 2017, 132, 479-485.	2.9	39

#	ARTICLE	IF	CITATIONS
91	Delayed Cerebral Vasculopathy Following Cranial Radiation Therapy for Pediatric Tumors. <i>Pediatric Neurology</i> , 2014, 50, 549-556.	2.1	38
92	Adjuvant chemotherapy and overall survival in adult medulloblastoma. <i>Neuro-Oncology</i> , 2017, 19, now150.	1.2	38
93	A new approach to understanding racial disparities in prostate cancer treatment. <i>Journal of Geriatric Oncology</i> , 2013, 4, 1-8.	1.0	37
94	Attitudes of radiation oncologists toward palliative and supportive care in the United States: Report on national membership survey by the American Society for Radiation Oncology (ASTRO). <i>Practical Radiation Oncology</i> , 2017, 7, 113-119.	2.1	36
95	CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 95.	2.8	36
96	Appropriate And Inappropriate Imaging Rates For Prostate Cancer Go Hand In Hand By Region, As If Set By Thermostat. <i>Health Affairs</i> , 2012, 31, 730-740.	5.2	35
97	Melanoma Brain Metastases: Is It Time to Reassess the Bias?. <i>Current Problems in Cancer</i> , 2011, 35, 200-210.	2.0	33
98	Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju008.	6.3	33
99	Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer. <i>European Urology</i> , 2017, 72, 738-744.	1.9	33
100	Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. <i>Radiotherapy and Oncology</i> , 2020, 148, 235-242.	0.6	33
101	Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort. <i>Cancer</i> , 2010, 116, 5757-5766.	4.1	32
102	Defining the High-Risk Population for Mortality After Resection of Early Stage NSCLC. <i>Clinical Lung Cancer</i> , 2015, 16, e183-e187.	2.6	32
103	BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study. <i>Neurosurgery</i> , 2019, 84, 868-880.	1.1	32
104	Postmastectomy radiation therapy for lymph node-negative, locally advanced breast cancer after modified radical mastectomy. <i>Cancer</i> , 2008, 113, 38-47.	4.1	31
105	The Impact of Pretreatment Prostate Volume on Severe Acute Genitourinary Toxicity in Prostate Cancer Patients Treated With Intensity-Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 379-384.	0.8	31
106	Variation in Treatment Recommendations of Adjuvant Radiation Therapy for High-risk Prostate Cancer by Physician Specialty. <i>Urology</i> , 2013, 82, 807-813.	1.0	31
107	Gamma Knife radiosurgery for facial nerve schwannomas: a multicenter study. <i>Journal of Neurosurgery</i> , 2015, 123, 387-394.	1.6	31
108	Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 486-490.	1.3	30

#	ARTICLE	IF	CITATIONS
109	Association between Time since Cancer Diagnosis and Health-Related Quality of Life: A Population-Level Analysis. <i>Value in Health</i> , 2016, 19, 631-638.	0.3	30
110	Radiation dose and cardiac risk in breast cancer treatment: An analysis of modern radiation therapy including community settings. <i>Practical Radiation Oncology</i> , 2018, 8, e79-e86.	2.1	30
111	Complications of Brain Tumors and Their Treatment. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 779-796.	2.2	29
112	Prophylactic Cranial Irradiation for Patients With Locally Advanced Non-Small-Cell Lung Cancer at High Risk for Brain Metastases. <i>Clinical Lung Cancer</i> , 2015, 16, 292-297.	2.6	29
113	Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort. <i>Urology</i> , 2016, 95, 88-94.	1.0	29
114	Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data Base. <i>Gynecologic Oncology</i> , 2016, 142, 54-61.	1.4	29
115	Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 663-672.	0.8	29
116	Emergency Department Visits for Opioid Overdoses Among Patients With Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 938-943.	6.3	29
117	The influence of regional health system characteristics on the surgical management and receipt of post operative radiation therapy for glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2013, 112, 393-401.	2.9	28
118	The global cancer divide: Relationships between national healthcare resources and cancer outcomes in high-income vs. middle- and low-income countries. <i>Journal of Epidemiology and Global Health</i> , 2014, 4, 115.	2.9	28
119	Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases. <i>Journal of Neurosurgery</i> , 2016, 125, 18-25.	1.6	28
120	The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 1011-1020.	0.8	28
121	Testicular Doses in Image-Guided Radiotherapy of Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e39-e47.	0.8	27
122	National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. <i>Cancer</i> , 2016, 122, 3371-3377.	4.1	27
123	Radiation Oncology Practice: Adjusting to a New Reimbursement Model. <i>Journal of Oncology Practice</i> , 2016, 12, e576-e583.	2.5	27
124	National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. <i>Cancer</i> , 2016, 122, 1505-1512.	4.1	27
125	Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 479-483.	2.5	27
126	Racial disparities in the use of SBRT for treating early-stage lung cancer. <i>Lung Cancer</i> , 2015, 89, 133-138.	2.0	26

#	ARTICLE	IF	CITATIONS
127	Treatment Burden of Medicare Beneficiaries With Stage I Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e98-e107.	2.5	26
128	Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 39-45.	1.7	26
129	The impact of county-level radiation oncologist density on prostate cancer mortality in the United States. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 391-396.	3.9	25
130	Variation in Receipt of Radiation Therapy After Breast-conserving Surgery. <i>Medical Care</i> , 2013, 51, 330-338.	2.4	25
131	Temporal Trends in Opioid Prescribing Patterns Among Oncologists in the Medicare Population. <i>Journal of the National Cancer Institute</i> , 2021, 113, 274-281.	6.3	25
132	Concurrent chemoradiotherapy versus radiotherapy alone for biopsy-only glioblastoma multiforme. <i>Cancer</i> , 2016, 122, 2364-2370.	4.1	24
133	National treatment trends among older patients with T1-localized renal cell carcinoma. Dr. Simon P. Kim is supported by a career development award from the Conquer Cancer Foundation from the American Society of Clinical Oncology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 113.e15-113.e21.	1.6	24
134	Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study. <i>Prostate</i> , 2017, 77, 437-445.	2.3	24
135	Development and Validation of a Multiparameterized Artificial Neural Network for Prostate Cancer Risk Prediction and Stratification. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-10.	2.1	24
136	Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. <i>Cancer</i> , 2018, 124, 752-759.	4.1	23
137	Significance of histology in determining management of lesions regrowing after radiosurgery. <i>Journal of Neuro-Oncology</i> , 2014, 117, 303-310.	2.9	22
138	Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2016, 121, 294-298.	0.6	22
139	Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 845-853.	0.8	22
140	A significant decrease in rectal volume and diameter during prostate IMRT. <i>Radiotherapy and Oncology</i> , 2011, 98, 187-191.	0.6	21
141	Patterns of Care and Outcomes Associated With Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Older Patients With Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e101-e107.	0.8	21
142	Role of stereotactic radiosurgery in patients with more than four brain metastases. <i>CNS Oncology</i> , 2013, 2, 181-193.	3.0	21
143	Travel distance and stereotactic body radiotherapy for localized prostate cancer. <i>Cancer</i> , 2018, 124, 1141-1149.	4.1	21
144	Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 209-216.	2.5	21

#	ARTICLE	IF	CITATIONS
145	Adoption of Intensity Modulated Radiation Therapy For Early-Stage Breast Cancer From 2004 Through 2011. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 303-311.	0.8	20
146	Minimum Data Elements for Radiation Oncology: An American Society for Radiation Oncology Consensus Paper. <i>Practical Radiation Oncology</i> , 2019, 9, 395-401.	2.1	20
147	Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis. <i>Radiotherapy and Oncology</i> , 2019, 132, 188-196.	0.6	20
148	Artificial Intelligence in Radiation Oncology Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1159-1161.	0.8	19
149	Is Proton Therapy a "Pro" for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database. <i>Frontiers in Oncology</i> , 2019, 8, 678.	2.8	19
150	Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 163-167.	1.3	19
151	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020, 5, 26-32.	1.2	19
152	Understanding Regional Variation in Medicare Expenditures for Initial Episodes of Prostate Cancer Care. <i>Medical Care</i> , 2014, 52, 680-687.	2.4	18
153	Geographic Access to Radiation Therapy Facilities in the United States. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 600-610.	0.8	18
154	Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. <i>Annals of Oncology</i> , 2018, 29, 386-391.	1.2	17
155	Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: an update. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1731-1738.	2.4	16
156	Cross Talk Between Estradiol and mTOR Kinase in the Regulation of Ovarian Granulosa Proliferation. <i>Reproductive Sciences</i> , 2012, 19, 143-151.	2.5	16
157	Examination of Industry Payments to Radiation Oncologists in 2014 Using the Centers for Medicare and Medicaid Services Open Payments Database. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 19-26.	0.8	16
158	US radiation oncology practice patterns for posttreatment survivor care. <i>Practical Radiation Oncology</i> , 2016, 6, 50-56.	2.1	16
159	A Dosimetric Evaluation of Conventional Helmet Field Irradiation Versus Two-Field Intensity-Modulated Radiotherapy Technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 621-631.	0.8	15
160	Patient Perspectives Regarding the Value of Total Skin Electron Beam Therapy for Cutaneous T-Cell Lymphoma/Mycosis Fungoides. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 142-144.	1.3	15
161	Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods. <i>Health Affairs</i> , 2015, 34, 592-600.	5.2	15
162	Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 568-574.	1.3	15

#	ARTICLE	IF	CITATIONS
163	Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. <i>Cancer</i> , 2019, 125, 3338-3346.	4.1	15
164	Adjuvant radiotherapy after radical prostatectomy: Evidence and analysis. <i>Cancer Treatment Reviews</i> , 2011, 37, 89-96.	7.7	14
165	Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 431-439.	2.5	14
166	The Association Between Evaluation at Academic Centers and the Likelihood of Expectant Management in Low-risk Prostate Cancer. <i>Urology</i> , 2016, 96, 128-135.	1.0	14
167	Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1113-1118.	0.8	14
168	Hypofractionated radiation therapy for prostate cancer: risks and potential benefits in a fiscally conservative health care system. <i>Oncology</i> , 2012, 26, 512-8.	0.5	14
169	The impact of cobalt-60 source age on biologically effective dose in high-dose functional Gamma Knife radiosurgery. <i>Journal of Neurosurgery</i> , 2016, 125, 154-159.	1.6	13
170	Surgeon peer network characteristics and adoption of new imaging techniques in breast cancer: A study of perioperative MRI. <i>Cancer Medicine</i> , 2018, 7, 5901-5909.	2.8	13
171	The Future of Artificial Intelligence in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 247-248.	0.8	13
172	Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?. <i>Translational Research</i> , 2019, 208, 63-72.	5.0	13
173	An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 454-489.	329.8	13
174	Using the Surveillance, Epidemiology, and End Results Database to Investigate Rare Cancers, Second Malignancies, and Trends in Epidemiology, Treatment, and Outcomes. <i>Current Problems in Cancer</i> , 2012, 36, 191-199.	2.0	12
175	Comparative Effectiveness Research in Radiation Oncology: Stereotactic Radiosurgery, Hypofractionation, and Brachytherapy. <i>Seminars in Radiation Oncology</i> , 2014, 24, 35-42.	2.2	12
176	Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 134, 44-49.	0.6	12
177	A general-purpose Monte Carlo particle transport code based on inverse transform sampling for radiotherapy dose calculation. <i>Scientific Reports</i> , 2020, 10, 9808.	3.3	12
178	Short-term complications and use of breast brachytherapy in the national Medicare population in 2008-2009.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1030-1030.	1.6	12
179	Decision Analysis of Stereotactic Radiation Surgery Versus Stereotactic Radiation Surgery and Whole-Brain Radiation Therapy for 1 to 3 Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 563-568.	0.8	11
180	Association between Surgeon and Hospital Characteristics and Lymph Node Counts From Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>Urology</i> , 2015, 85, 890-895.	1.0	11

#	ARTICLE	IF	CITATIONS
181	Hypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales. <i>Journal of Clinical Oncology</i> , 2017, 35, 1867-1869.	1.6	11
182	Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 495-501.	1.3	11
183	The Relationship Between Clinical Benefit and Receipt of Curative Therapy for Prostate Cancer. <i>Archives of Internal Medicine</i> , 2012, 172, 362.	3.8	10
184	National Residency Matching Program (NRMP) Results for Radiation Oncology: 2011 Update. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 771-772.	0.8	10
185	Radiosurgical Dose Selection for Brain Metastasis. <i>Progress in Neurological Surgery</i> , 2012, 25, 139-147.	1.3	10
186	Emerging Technologies and Techniques in Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2017, 27, 34-42.	2.2	10
187	Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. <i>European Urology Oncology</i> , 2019, 2, 189-195.	5.4	10
188	Perceptions of Barriers Towards Active Surveillance for Low-Risk Prostate Cancer: Results From a National Survey of Radiation Oncologists and Urologists. <i>Annals of Surgical Oncology</i> , 2019, 26, 660-668.	1.5	10
189	Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2021, 154, 197-203.	2.9	10
190	Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. <i>Cancer Letters</i> , 2022, 526, 346-351.	7.2	10
191	Hospital Frailty Risk Score and healthcare resource utilization after surgery for metastatic spinal column tumors. <i>Journal of Neurosurgery: Spine</i> , 2022, 37, 241-251.	1.7	10
192	Hippocampal-Sparing Whole-Brain Radiotherapy: A "How-To" Technique Using Helical Tomotherapy and Linear Accelerator-Based Intensity-Modulated Radiotherapy: In Regard to Gondi V, et al. (<i>Int J Radiat Oncol Biol Phys</i>) 2019; 107:957-958.	8.8	9
193	Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base. <i>Annals of Thoracic Surgery</i> , 2014, 97, 1149-1155.	1.3	9
194	Differences in Funding Sources of Phase III Oncology Clinical Trials by Treatment Modality and Cancer Type. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 312-317.	1.3	9
195	Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. <i>Urology</i> , 2019, 124, 98-106.	1.0	9
196	Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 46-52.	1.7	9
197	Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 414-422.	3.9	9
198	Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. <i>PLoS ONE</i> , 2017, 12, e0184747.	2.5	9

#	ARTICLE	IF	CITATIONS
199	National Residency Matching Program (NRMP) Results for Radiation Oncology: 2007 Update. International Journal of Radiation Oncology Biology Physics, 2007, 69, 326-327.	0.8	8
200	For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery. Surgery, 2014, 155, 776-788.	1.9	8
201	Increased Number of Beam Angles Is Associated With Higher Cardiac Dose in Adjuvant Fixed Gantry Intensity Modulated Radiation Therapy of Left-Sided Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1137-1145.	0.8	8
202	Peer support: A needs assessment for social support from trained peers in response to stress among medical physicists. Journal of Applied Clinical Medical Physics, 2019, 20, 157-162.	1.9	8
203	Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis. Anticancer Research, 2019, 39, 2911-2918.	1.1	8
204	Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 619-627.	1.6	8
205	Persistent Use of Extended Fractionation Palliative Radiotherapy for Medicare Beneficiaries With Metastatic Breast Cancer, 2011 to 2014. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 493-499.	1.3	8
206	Perceptions of Prostate MRI and Fusion Biopsy of Radiation Oncologists and Urologists for Patients Diagnosed with Prostate Cancer: Results from a National Survey. European Urology Focus, 2020, 6, 273-279.	3.1	8
207	Nationwide Patterns of Pathologic Fractures Among Patients Hospitalized With Bone Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 720-726.	1.3	8
208	Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. Journal of Clinical Oncology, 2021, 39, 2386-2396.	1.6	8
209	The Prognostic Importance of Midline Involvement in Oral Tongue Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 468-473.	1.3	7
210	How Radiation Oncologists Would Disclose Errors: Results of a Survey of Radiation Oncologists and Trainees. International Journal of Radiation Oncology Biology Physics, 2012, 84, e131-e137.	0.8	7
211	Impact of preoperative radiation on survival of patients with T3N0 >7-cm non-small cell lung cancers treated with anatomic resection using the Surveillance, Epidemiology, and End Results database. Journal of Surgical Research, 2013, 184, 10-18.	1.6	7
212	Is It the Time for Personalized Imaging Protocols in Cancer Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2015, 91, 659-660.	0.8	7
213	Academic and Resident Radiation Oncologists' Attitudes and Intentions Regarding Radiation Therapy near the End of Life. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 85-89.	1.3	7
214	Economic Burden Associated with Hospitalization for Radiation Cystitis: Results from a Statewide Inpatient Database. Urology Practice, 2016, 3, 437-442.	0.5	7
215	Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 501.e15-501.e21.	1.6	7
216	Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. Current Oncology Reports, 2018, 20, 66.	4.0	7

#	ARTICLE	IF	CITATIONS
217	Drivers of Medicare Spending: A 15-Year Review of Radiation Oncology Charges Allowed by the Medicare Physician/Supplier Fee-for-Service Program Compared With Other Specialties. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 322-327.	0.8	7
218	Social Connectedness Among Medicare Beneficiaries Following the Onset of the COVID-19 Pandemic. <i>JAMA Internal Medicine</i> , 2021, 181, 1245.	5.1	7
219	Mibefradil dihydrochloride with hypofractionated radiation for recurrent glioblastoma: A phase I dose expansion trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14046-e14046.	1.6	7
220	A contemporary dose selection algorithm for stereotactic radiosurgery in the treatment of brain metastases - An initial report. <i>Journal of Radiosurgery and SBRT</i> , 2016, 4, 43-52.	0.2	7
221	National Residency Matching Program Results for Radiation Oncology: 2012 Update. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 402-404.	0.8	6
222	Stereotactic body radiation therapy: Let's not give up on progress. <i>Practical Radiation Oncology</i> , 2015, 5, 193-196.	2.1	6
223	Association Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 152-158.	1.3	6
224	Association between Long-Term Second Malignancy Risk and Radiation: A Comprehensive Analysis of the Entire Surveillance, Epidemiology, and End Results Database (1973-2014). <i>Advances in Radiation Oncology</i> , 2019, 4, 738-747.	1.2	6
225	Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer. <i>JAMA Network Open</i> , 2020, 3, e2017144.	5.9	6
226	Health State Utilities for Patients with Brain Metastases. <i>Cureus</i> , 2016, 8, e667.	0.5	6
227	Health Economics Research in Cancer Treatment: Current Challenges and Future Directions. <i>Journal of the National Cancer Institute Monographs</i> , 2022, 2022, 51-56.	2.1	6
228	National Residency Matching Program (NRMP) Results for Radiation Oncology: 2010 Update. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 4-5.	0.8	5
229	Role of Neurosurgery and Radiation Therapy in the Management of Brain Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 757-777.	2.2	5
230	Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw281.	6.3	5
231	Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinoma. <i>Brachytherapy</i> , 2018, 17, 399-406.	0.5	5
232	Analysis of the 2017 American Society for Radiation Oncology (ASTRO) Research Portfolio. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 297-304.	0.8	5
233	A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e472-e481.	1.9	5
234	Breast cancer patients with brain metastasis undergoing GKRS. <i>Breast Cancer</i> , 2019, 26, 147-153.	2.9	5

#	ARTICLE	IF	CITATIONS
235	Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2033787.	5.9	5
236	Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 786.e1-786.e8.	1.6	5
237	An Update to Changing Patterns of Anal Carcinoma in the United States. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 887-897.	1.3	5
238	The Role of Postoperative Radiation Therapy (PORT) in the Treatment of Extrahepatic Bile Duct Cancer: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Investigation. <i>Journal of Gastrointestinal Cancer</i> , 2008, 39, 11-21.	1.3	4
239	Impact of Immediate Postoperative Death on the Estimation of a Survival Benefit From Postoperative Radiation Therapy for Cancer of the Gallbladder. <i>Journal of Clinical Oncology</i> , 2008, 26, 4523-4523.	1.6	4
240	Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 8-10.	0.8	4
241	Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. <i>Journal of Neuro-Oncology</i> , 2018, 136, 289-298.	2.9	4
242	Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1062-1068.	1.3	4
243	The Association between the Affordable Care Act and Insurance Status, Stage and Treatment in Patients with Testicular Cancer. <i>Urology Practice</i> , 2020, 7, 252-258.	0.5	4
244	Nationwide patterns of hemorrhagic stroke among patients hospitalized with brain metastases: influence of primary cancer diagnosis and anticoagulation. <i>Scientific Reports</i> , 2020, 10, 10084.	3.3	4
245	Responses to the 2018 and 2019 "One Big Discovery" Question: ASTRO Membership's Opinions on the Most Important Research Question Facing Radiation Oncology Where Are We Headed?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 38-40.	0.8	4
246	Use of alternative medicine for cancer and its impact on survival.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18175-e18175.	1.6	4
247	Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1079-1079.	1.6	4
248	In regard to "Indications for Pelvic Nodal Treatment in Prostate Cancer Should Change. Validation of the Roach Formula in a Large Extended Nodal Dissection Series." (<i>Int J Radiat Oncol Biol Phys</i>) Tj ETQq0 0 0 rgBT /08erlock 30 Tf 50 21		
249	Revisiting the Sustainable Growth Rate "Hole" Sources of Healthcare Cost Stabilization in 2010-2012. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 983-985.	0.8	3
250	Perceptions of Radiation Oncologists and Urologists on Sources and Type of Evidence to Inform Prostate Cancer Treatment Decisions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 277-283.	0.8	3
251	Historical trends of radiotherapy use in prevalent malignancies over 38 years in SEER. <i>Journal of Radiation Oncology</i> , 2015, 4, 11-17.	0.7	3
252	Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas. <i>Radiotherapy and Oncology</i> , 2017, 125, 258-265.	0.6	3

#	ARTICLE	IF	CITATIONS
253	Association between access to accelerated partial breast irradiation and use of adjuvant radiotherapy. <i>Cancer</i> , 2017, 123, 502-511.	4.1	3
254	Medicare Cancer Screening in the Context of Clinical Guidelines. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 339-347.	1.3	3
255	The case for radiotherapy in a Value based environment. <i>Reports of Practical Oncology and Radiotherapy</i> , 2019, 24, 200-203.	0.6	3
256	Resident attitudes and benefits of mock oral board examinations in radiation oncology. <i>BMC Medical Education</i> , 2020, 20, 203.	2.4	3
257	Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 327-330.	5.4	3
258	Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening. <i>Cancer Control</i> , 2020, 27, 107327482090226.	1.8	3
259	Digital health application for real-time patient-reported outcomes during prostate radiotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 157-157.	1.6	3
260	RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5601-TPS5601.	1.6	3
261	Reply to L.W. Cuttino et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 2227-2229.	1.6	2
262	Hypofractionated radiation therapy versus conventionally fractionated radiation therapy for early-stage breast cancer: how do we choose?. <i>Future Oncology</i> , 2015, 11, 2105-2107.	2.4	2
263	Ceritinib enables stereotactic radiosurgery to a previously untreatable symptomatic brain metastasis in a patient with ALK rearranged non-small cell lung cancer. <i>Cancer Treatment Communications</i> , 2016, 6, 17-19.	0.4	2
264	Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 97-106.	0.8	2
265	Radiation Therapy for Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2019, 3, 1-6.	0.4	2
266	Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. <i>Obstetrical and Gynecological Survey</i> , 2019, 74, 217-219.	0.4	2
267	Peer Influence on Physician Use of Shorter Course External Beam Radiation Therapy for Patients with Breast Cancer. <i>Practical Radiation Oncology</i> , 2020, 10, 75-83.	2.1	2
268	Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques. <i>Lung Cancer</i> , 2021, 161, 171-179.	2.0	2
269	Diffusion of stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) in the Medicare population, 2007-2009.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7575-7575.	1.6	2
270	National trends in the management of patients with positive surgical margins at the time of radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 111-111.	1.6	2

#	ARTICLE	IF	CITATIONS
271	National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , 1-6.	4.9	2
272	Attitudes of radiation oncologists toward palliative and supportive care in the United States: Report on National Membership Survey by the American Society for Radiation Oncology (ASTRO).. <i>Journal of Clinical Oncology</i> , 2016, 34, 105-105.	1.6	2
273	Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19309-e19309.	1.6	2
274	The cost of cancer-related physician services to Medicare. <i>Yale Journal of Biology and Medicine</i> , 2015, 88, 107-14.	0.2	2
275	Spine Stereotactic Body Radiotherapy Outcomes in Patients with Concurrent Brain Metastases. <i>Cureus</i> , 2016, 8, e679.	0.5	2
276	Impact of Frailty on Morbidity and Mortality in Adult Patients Undergoing Surgical Evacuation of Acute Traumatic Subdural Hematoma. <i>World Neurosurgery</i> , 2022, 162, e251-e263.	1.3	2
277	Prediction Models, Nomograms, and Staging Validation with the Surveillance, Epidemiology, and End Results Database. <i>Current Problems in Cancer</i> , 2012, 36, 200-207.	2.0	1
278	Comparative Effectiveness Research and the Surveillance, Epidemiology, and End Results Database. <i>Current Problems in Cancer</i> , 2012, 36, 208-215.	2.0	1
279	Interpreting cost-utility analysis of prostate cancer treatment. <i>Nature Reviews Urology</i> , 2013, 10, 129-131.	3.8	1
280	Determinants of Enrollment in Cancer Clinical Trials: The Relationship Between the Current State of Knowledge, Societal Disease Burden, and Randomized Clinical Trial Enrollment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 928-936.	4.9	1
281	Intensity Modulated Radiotherapy and Image Guidance. , 2016, , 413-426.		1
282	Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1718-1722.	1.6	1
283	Reply to timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. <i>Cancer</i> , 2016, 122, 3577-3578.	4.1	1
284	Responses to the 2017 "1 Million Gray Question": ASTRO Membership's Opinions on the Most Important Research Question Facing Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 249-250.	0.8	1
285	Probing peripheral neural pathways in electrically stimulation induced sensation. , 2019, ,		1
286	Methodology Flaws and Implications of a Complementary Medicine Study" In Reply. <i>JAMA Oncology</i> , 2019, 5, 433.	7.1	1
287	The ASTRO Research Portfolio: Where Do We Go From Here?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 308-309.	0.8	1
288	Proton-Based Chemoradiotherapy" What Level of Evidence Is Necessary to Justify Its Widespread Use?. <i>JAMA Oncology</i> , 2020, 6, 246.	7.1	1

#	ARTICLE	IF	CITATIONS
289	Income disparities in needle biopsy patients prior to breast cancer surgery across physician peer groups. <i>Breast Cancer</i> , 2020, 27, 381-388.	2.9	1
290	Physician trajectories of abandoning long-course breast radiotherapy and their cost impact. <i>Health Services Research</i> , 2021, 56, 497-506.	2.0	1
291	Did quality of life for older cancer survivors improve with the turn of the century in the United States?. <i>Journal of Geriatric Oncology</i> , 2021, 12, 102-105.	1.0	1
292	The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100143.	1.1	1
293	For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6511-6511.	1.6	1
294	Estimating the impact of screening on three decades of cervical cancer incidence.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1518-1518.	1.6	1
295	“The burden upon me”: The complexity of healthcare utilization among Medicare patients undergoing curative lung cancer treatment.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7533-7533.	1.6	1
296	Association between radiation dose and outcomes with postoperative radiotherapy for NO-N1 non-small-cell-lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7538-7538.	1.6	1
297	Changes in prostate cancer presentation for radiation oncology care after USPSTF recommendations, 2007-2013.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16070-e16070.	1.6	1
298	Factors associated with high-volume providers of stereotactic radiation therapy for Medicare beneficiaries in 2012.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17578-e17578.	1.6	1
299	CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis: An integrated genomic and clinical TCGA analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6060-6060.	1.6	1
300	Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database.. <i>Journal of Clinical Oncology</i> , 2019, 37, 12-12.	1.6	1
301	Long-term Quality of Life in Survivors of Brain Metastases: A Roller Coaster of Perspective. <i>Cureus</i> , 2018, 10, e2358.	0.5	1
302	Abandonment trajectories of conventionally fractionated adjuvant radiotherapy in breast cancer care.. <i>Journal of Clinical Oncology</i> , 2019, 37, 531-531.	1.6	1
303	Temporal trends in opioid prescribing patterns among oncologists in the Medicare population.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12022-12022.	1.6	1
304	Predicting treatment related imaging changes (TRICs) after radiosurgery for brain metastases using treatment dose and conformality metrics. <i>Journal of Radiosurgery and SBRT</i> , 2016, 4, 53-60.	0.2	1
305	Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery. <i>Journal of Radiosurgery and SBRT</i> , 2016, 4, 97-106.	0.2	1
306	Equivalent whole brain dose for patients undergoing gamma knife for multiple lesions. <i>Journal of Radiosurgery and SBRT</i> , 2015, 3, 187-191.	0.2	1

#	ARTICLE	IF	CITATIONS
307	Emergency Department Visits for Radiation Cystitis Among Patients with a Prostate Cancer History. <i>BJU International</i> , 2021, , .	2.5	1
308	Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole-Brain Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2022, 7, 100949.	1.2	1
309	In Response to Dr. Hayes and Colleagues. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1598-1599.	0.8	0
310	In Reply to Drs. Oymak and Onal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1603-1604.	0.8	0
311	The relation between age and androgen deprivation therapy use among men in the Medicare population receiving radiation therapy for prostate cancer. <i>Journal of Geriatric Oncology</i> , 2013, 4, 9-18.	1.0	0
312	Response. <i>Journal of the National Cancer Institute</i> , 2013, 105, 748-749.	6.3	0
313	Response. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju198-dju198.	6.3	0
314	Reply to K. Quan et al, S.P. Collins et al, C.R. King et al, S. Arcangeli et al, D.B. Fuller, and D. Vordermark. <i>Journal of Clinical Oncology</i> , 2014, 32, 3456-3457.	1.6	0
315	In Reply to Wang etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 211-213.	0.8	0
316	In Reply to Rusthoven and Kavanagh. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 680-681.	0.8	0
317	Change in radiotherapy treatment volumes with initial alkylating chemotherapy in anaplastic gliomas. <i>Journal of Radiation Oncology</i> , 2015, 4, 163-167.	0.7	0
318	Author Reply. <i>Urology</i> , 2016, 96, 134-135.	1.0	0
319	Reply to J. Du et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 4451-4452.	1.6	0
320	Changes in quality of life after radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapy. <i>Journal of Radiation Oncology</i> , 2017, 6, 295-300.	0.7	0
321	Reply to A. Chalmers et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 2340-2341.	1.6	0
322	The Death Spiral of Cancer and Financial Hardship. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky013.	2.9	0
323	AUTHOR REPLY. <i>Urology</i> , 2019, 124, 106.	1.0	0
324	Results of a pilot/phase II study of gamma knife radiosurgery for brain metastases and implications for future prospective clinical trials. <i>Journal of Radiation Oncology</i> , 2019, 8, 39-46.	0.7	0

#	ARTICLE	IF	CITATIONS
325	Radiation Dose to the Rectum With Definitive Radiation Therapy and Hydrogel Spacer Versus Postprostatectomy Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2020, 5, 1225-1231.	1.2	0
326	National trends in the management of patients with positive surgical margins at radical prostatectomy. <i>World Journal of Urology</i> , 2021, 39, 1141-1151.	2.2	0
327	Association between percentage of positive biopsy cores and risk of pelvic lymph node involvement in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 205-205.	1.6	0
328	Adoption of consolidative durvalumab among patients with locally advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20550-e20550.	1.6	0
329	Practical Radiation Oncology's Top 20 Downloads of 2020. <i>Practical Radiation Oncology</i> , 2021, 11, 233-235.	2.1	0
330	The influence of regional radiation oncologist and urologist capacities on treatment choice for prostate cancer management.. <i>Journal of Clinical Oncology</i> , 2012, 30, 108-108.	1.6	0
331	An assessment of the collective efforts of clinical trials to provide evidence-based practice guidelines in cancer care.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6019-6019.	1.6	0
332	Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4651-4651.	1.6	0
333	The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15150-e15150.	1.6	0
334	The cost implications of prostate cancer screening in the Medicare population.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6549-6549.	1.6	0
335	Perceptions of radiation oncologists and urologists on the type of evidence that informs and changes the clinical practice of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 167-167.	1.6	0
336	Perceptions of radiation oncologists and urologists about new technology for the treatment of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16085-e16085.	1.6	0
337	Association between provider-level factors and lymph node dissection outcomes during radical prostatectomy: A national cancer database analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 89-89.	1.6	0
338	Association between geographic access to cancer care and receipt of chemotherapy: Geographic distribution of oncologists and travel distance.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17561-e17561.	1.6	0
339	Medicare cancer screening in the context of clinical guidelines: 2000-2012.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17579-e17579.	1.6	0
340	Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study. <i>Blood</i> , 2015, 126, 1676-1676.	1.4	0
341	Genomic predictors of biochemical failure following radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 114-114.	1.6	0
342	The impact of social contagion on physician adoption of breast cancer imaging.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6534-6534.	1.6	0

#	ARTICLE	IF	CITATIONS
343	The benefit of modern cancer therapy for older patients.. Journal of Clinical Oncology, 2016, 34, e18141-e18141.	1.6	0
344	A Novel Prognostic Index for Ocular Adnexal Lymphoma. Blood, 2016, 128, 3597-3597.	1.4	0
345	Trends and clinico-sociodemographic determinants of stereotactic body radiotherapy use for localized prostate cancer: A National Cancer Database study.. Journal of Clinical Oncology, 2017, 35, e545-e545.	1.6	0
346	Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.. Journal of Clinical Oncology, 2017, 35, 18-18.	1.6	0
347	Outcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance.. Journal of Clinical Oncology, 2017, 35, 198-198.	1.6	0
348	Association between metastatic free interval and recurrent metastatic breast cancer survival: Findings from the Surveillance, Epidemiology and End Results database.. Journal of Clinical Oncology, 2018, 36, e13069-e13069.	1.6	0
349	Comparative Effectiveness of SBRT. , 2019, , 415-424.		0
350	Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening.. Journal of Clinical Oncology, 2019, 37, 1567-1567.	1.6	0
351	Emergency department visits for prescription and synthetic opioid overdoses among patients with cancer.. Journal of Clinical Oncology, 2019, 37, 6579-6579.	1.6	0
352	Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer.. Journal of Clinical Oncology, 2020, 38, e19308-e19308.	1.6	0
353	Emergency Department Visits for Firearm-Related Injuries among Youth in the United States, 2006â€“2015. Journal of Law, Medicine and Ethics, 2020, 48, 67-73.	0.9	0
354	Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.. Journal of Clinical Oncology, 2020, 38, 748-748.	1.6	0
355	In regards to decision making for reirradiation of a recurrent intramedullary spinal cord metastasis. Journal of Radiosurgery and SBRT, 2014, 3, 165-168.	0.2	0
356	Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy. Journal of Radiosurgery and SBRT, 2020, 7, 19-27.	0.2	0
357	Impact of tissue heterogeneity correction on Gamma Knife stereotactic radiosurgery of acoustic neuromas. Journal of Radiosurgery and SBRT, 2021, 7, 207-212.	0.2	0
358	NIMG-03. DEEP LEARNING SURVIVAL ANALYSIS FOR MULTIPLE BRAIN METASTASES. Neuro-Oncology, 2020, 22, ii147-ii147.	1.2	0
359	Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice, 2022, 9, 140-149.	0.5	0
360	A reply to â€œRandomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLCâ€œ. Lung Cancer, 2022, 168, 84-85.	2.0	0

#	ARTICLE	IF	CITATIONS
361	PRO's Top 20 Downloads of 2021. Practical Radiation Oncology, 2022, 12, 176-178.	2.1	0
362	A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer.. Journal of Clinical Oncology, 2022, 40, TPS5115-TPS5115.	1.6	0
363	A Special Series on Radiopharmaceutical Therapy. Practical Radiation Oncology, 2022, 12, 283-284.	2.1	0
364	Evaluation of social connectedness, loneliness, and anxiety among cancer survivors during the 2020-2021 winter surge of COVID-19 pandemic.. Journal of Clinical Oncology, 2022, 40, 12061-12061.	1.6	0